ANCA Vasculitis and the Complement System, Part 1: The Mouse's Tale

This episode walks us through the initial research that paved the way for a game changing therapeutic in ANCA vasculitis, as well as the story of how host Adam J. Brown, MD, finally learned how to spell complement.

Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.

Intro :10
Welcome :21
Today's episode :24
So how did we get there? 4:18
How do we start teasing apart the effect of the complement in ANCA vasculitis? 8:13
Discussing and simplifying the mouse model 9:00
Quickly reviewing the complement cascade 12:06

Brought to you by GSK. Consider the long-term impact of disease activity flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com.

Taking the puzzle pieces away in the mouse model 17:04
What about the next steps? 22:05
What happens when you block C5a? 25:12
CCX168: Summing up the mouse tale 28:44
In the next episode 30:20
Thanks for listening 30:46

Disclosures: Brown reports no relevant financial disclosures.

We'd love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum

References:

Brilland B, et al. Autoimmun Rev. 2020;19:102424.

Freeley SJ, et al. J Pathol 2016;240:61-71.

Haas M, Eustace JA. Kidney Int 2004;65:2145-2152.

Huugen D, et al. Kidney Int 2007;71:646-654.

Marder SR, et al. Arg. J Immunol. 1985;134:3325-3331.

Schreiber A, et al. J Am Soc Nephrol. 2009;20:289-298.

Xiao H, et al. Am J Pathol. 2007;170:52-64.

Xiao H, et al. J Clin Invest 2002;110:955–963.

Xiao H, et al. J Am Soc Nephrol, 2014;25:225–231.